Corcept Therapeutics Inc. (NASDAQ:CORT) Director Patrick G. Enright sold 544,100 shares of the company’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $9.56, for a total transaction of $5,201,596.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Corcept Therapeutics Inc. (NASDAQ:CORT) opened at 9.35 on Tuesday. The firm’s 50-day moving average price is $7.54 and its 200 day moving average price is $6.14. Corcept Therapeutics Inc. has a 12 month low of $3.22 and a 12 month high of $10.00. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of 239.74 and a beta of 1.64.

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

A number of brokerages have recently issued reports on CORT. FBR & Co reissued a “buy” rating on shares of Corcept Therapeutics in a report on Thursday, August 4th. Zacks Investment Research raised shares of Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research note on Tuesday, October 18th. Finally, Piper Jaffray Cos. set a $12.00 target price on shares of Corcept Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 19th.

A number of hedge funds have recently modified their holdings of the company. Bank of Montreal Can purchased a new stake in shares of Corcept Therapeutics during the second quarter valued at $100,000. Smith Asset Management Group LP boosted its stake in shares of Corcept Therapeutics by 69.2% in the second quarter. Smith Asset Management Group LP now owns 30,080 shares of the company’s stock valued at $164,000 after buying an additional 12,300 shares in the last quarter. Falcon Point Capital LLC boosted its stake in shares of Corcept Therapeutics by 12.3% in the second quarter. Falcon Point Capital LLC now owns 96,575 shares of the company’s stock valued at $527,000 after buying an additional 10,569 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Corcept Therapeutics by 18.4% in the second quarter. Bank of New York Mellon Corp now owns 320,872 shares of the company’s stock valued at $1,752,000 after buying an additional 49,807 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in shares of Corcept Therapeutics by 19.5% in the second quarter. California State Teachers Retirement System now owns 156,638 shares of the company’s stock valued at $855,000 after buying an additional 25,574 shares in the last quarter. 41.24% of the stock is currently owned by hedge funds and other institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

5 Day Chart for NASDAQ:CORT

Receive News & Stock Ratings for Corcept Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Inc. and related stocks with our FREE daily email newsletter.